LONG TERM FOLLOW UP OF THE BATMO PROTOCOL (BEST-ANTIMICROBIAL-THERAPY-TMO) AND COMPARISON WITH HYSTORICAL DATA (EHA 2025) - May 16, 2025 - Abstract #S301; Pres time: Jun 13, 2025; 05:15 PM - 05:30 PM; Location: Brown Hall 1; "The main features of this protocol are the lack of fluoroquinolones prophylaxis during neutropenic phase of allo-SCT the administration of posaconazole in high-risk patients (pts) and of letermovir in CMV-positive pts from day 0 to day +100. Sistematic use of posaconazole as fungal prophylaxis is effective in maintaining a low incidence of proven/possible IFD despite the increase of risk factors (e.g. more Haplo donors in Cohort B). Data on the antimicrobial susceptibility of BSI isolates MDR-colonizing bacteria and the use of new antimicrobials are currently under investigation."
Clinical • Acute Graft versus Host Disease • Febrile Neutropenia • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Neutropenia • Pneumonia • Respiratory Diseases
|
|
Lorenzo Masina; Simone Ferri; Liana Signorini; Francesca Caccuri; Silvia Corbellini; Silvia Lorenzotti; Mirko Farina; Enrico Morello; Vera Radici; Gabriele Magliano; Daniele Avenoso; Arnaldo Caruso; Domenico Russo; Evelyn Van Hauwermeiren; Michele Malagola
|